Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC.

Riess JW, Gandara DR, Frampton GM, Madison R, Peled N, Bufill JA, Dy GK, Ou SI, Stephens PJ, McPherson JD, Lara PN Jr, Burich RA, Ross JS, Miller VA, Ali SM, Mack PC, Schrock AB.

J Thorac Oncol. 2018 Oct;13(10):1560-1568. doi: 10.1016/j.jtho.2018.06.019. Epub 2018 Jul 5.

PMID:
29981927
2.

In Search of an Oncogene Driver for Squamous Lung Cancer.

Gandara DR, Riess JW, Lara PN Jr.

JAMA Oncol. 2018 Sep 1;4(9):1197-1198. doi: 10.1001/jamaoncol.2018.0774. No abstract available.

PMID:
29902311
3.

Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance.

Turner DC, Kondic AG, Anderson KM, Robinson AG, Garon EB, Riess JW, Jain L, Mayawala K, Kang J, Ebbinghaus SW, Sinha V, de Alwis DP, Stone JA.

Clin Cancer Res. 2018 Jun 11. doi: 10.1158/1078-0432.CCR-18-0415. [Epub ahead of print]

PMID:
29891725
4.

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.

Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan DSW, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR.

J Thorac Oncol. 2018 Sep;13(9):1248-1268. doi: 10.1016/j.jtho.2018.05.030. Epub 2018 Jun 6. Review.

PMID:
29885479
5.

Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.

Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE, Gedmintas L, Azimi R, Rizvi H, Riess JW, Hellmann MD, Awad MM.

J Clin Oncol. 2018 Jul 1;36(19):1905-1912. doi: 10.1200/JCO.2017.77.0305. Epub 2018 May 10.

PMID:
29746230
6.

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).

Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, Foster NR, Riess JW, Agulnik M, Chang AYC, Chopra A, Kish JA, Chung CH, Adkins DR, Cullen KJ, Gitlitz BJ, Lim DW, To KF, Chan KCA, Lo YMD, King AD, Erlichman C, Yin J, Costello BA, Chan ATC.

J Clin Oncol. 2018 May 10;36(14):1412-1418. doi: 10.1200/JCO.2017.77.0388. Epub 2018 Mar 27.

PMID:
29584545
7.

Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck.

Trieu V, Pinto H, Riess JW, Lira R, Luciano R, Coty J, Boothroyd D, Colevas AD.

Oncologist. 2018 Jul;23(7):764-e86. doi: 10.1634/theoncologist.2017-0618. Epub 2018 Mar 14.

8.

Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions.

Floc'h N, Martin MJ, Riess JW, Orme JP, Staniszewska AD, Ménard L, Cuomo ME, O'Neill DJ, Ward RA, Finlay MRV, McKerrecher D, Cheng M, Vang DP, Burich RA, Keck JG, Gandara DR, Mack PC, Cross DAE.

Mol Cancer Ther. 2018 May;17(5):885-896. doi: 10.1158/1535-7163.MCT-17-0758. Epub 2018 Feb 26.

PMID:
29483211
9.

Functional Outcomes After De-escalated Chemoradiation Therapy for Human Papillomavirus-Positive Oropharyngeal Cancer: Secondary Analysis of a Phase 2 Trial.

Hegde JV, Shaverdian N, Felix C, Wang PC, Veruttipong D, Hsu S, Riess JW, Rao SD, Daly ME, Chen AM.

Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):647-651. doi: 10.1016/j.ijrobp.2017.10.045. Epub 2017 Nov 6.

PMID:
29246721
10.

Computed Tomography Features associated With the Eighth Edition TNM Stage Classification for Thymic Epithelial Tumors.

Padda SK, Terrone D, Tian L, Khuong A, Neal JW, Riess JW, Berry MF, Hoang CD, Burt BM, Leung AN, Schwartz EJ, Shrager JB, Wakelee HA.

J Thorac Imaging. 2018 May;33(3):176-183. doi: 10.1097/RTI.0000000000000310.

PMID:
29219888
11.

Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database.

Padda SK, Yao X, Antonicelli A, Riess JW, Shang Y, Shrager JB, Korst R, Detterbeck F, Huang J, Burt BM, Wakelee HA, Badve SS.

J Thorac Oncol. 2018 Mar;13(3):436-446. doi: 10.1016/j.jtho.2017.11.118. Epub 2017 Nov 27.

PMID:
29191778
12.

Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer Registry.

Lara JD, Brunson A, Riess JW, Kelly K, Lara PN Jr, Gandara DR.

Lung Cancer. 2017 Oct;112:165-168. doi: 10.1016/j.lungcan.2017.08.015. Epub 2017 Aug 31.

PMID:
29191590
13.

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.

Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack PC, Gandara DR, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG.

Nat Genet. 2017 Dec;49(12):1693-1704. doi: 10.1038/ng.3990. Epub 2017 Nov 6.

14.

Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial.

Hegde JV, Shaverdian N, Daly ME, Felix C, Wong DL, Rosove MH, Garst JH, Wang PC, Veruttipong D, Rao S, Fragoso RC, Riess JW, Steinberg ML, Chen AM.

Cancer. 2018 Feb 1;124(3):521-529. doi: 10.1002/cncr.30954. Epub 2017 Oct 17.

15.

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A.

J Clin Oncol. 2017 May 1;35(13):1403-1410. doi: 10.1200/JCO.2016.70.9352. Epub 2017 Mar 13.

16.

Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer.

Gandara DR, Riess JW, Kelly K, Li T, Mack PC, Lara PN Jr.

Clin Lung Cancer. 2017 Jan;18(1):1-4. doi: 10.1016/j.cllc.2016.12.011. Epub 2016 Dec 24.

PMID:
28082049
17.

Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer.

Riess JW, Lara PN Jr, Gandara DR.

J Clin Oncol. 2016 Nov 1;34(31):3717-3718. doi: 10.1200/JCO.2016.69.0040. No abstract available.

18.

Multidisciplinary Care.

Daly ME, Riess JW.

Cancer Treat Res. 2016;170:285-300. doi: 10.1007/978-3-319-40389-2_13. Review.

PMID:
27535399
19.

Pruritus as a Paraneoplastic Symptom of Thymoma.

Padda SK, Shrager JB, Riess JW, Pagtama JY, Holmes Tisch AJ, Kwong BY, Liang Y, Schwartz EJ, Loo BW, Neal JW, Hardy R, Wakelee HA.

J Thorac Oncol. 2015 Nov;10(11):e110-2. doi: 10.1097/JTO.0000000000000623. No abstract available.

20.

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.

Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG.

Nat Med. 2015 Sep;21(9):1038-47. doi: 10.1038/nm.3930. Epub 2015 Aug 24.

21.

Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction.

Das M, Padda SK, Frymoyer A, Zhou L, Riess JW, Neal JW, Wakelee HA.

Lung Cancer. 2015 Sep;89(3):280-6. doi: 10.1016/j.lungcan.2015.06.011. Epub 2015 Jun 22.

22.

Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform.

Gandara DR, Mack PC, Bult C, Li T, Lara PN Jr, Riess JW, Astrow SH, Gandour-Edwards R, Cooke DT, Yoneda KY, Moore EH, Pan CX, Burich RA, David EA, Keck JG, Airhart S, Goodwin N, de Vere White RW, Liu ET.

Clin Lung Cancer. 2015 May;16(3):165-72. doi: 10.1016/j.cllc.2015.03.001. Epub 2015 Mar 18.

23.

GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray.

Riess JW, West R, Dean M, Klimowicz AC, Neal JW, Hoang C, Wakelee HA.

Anticancer Res. 2015 Feb;35(2):669-76.

24.

Pemetrexed in patients with thymic malignancies previously treated with chemotherapy.

Liang Y, Padda SK, Riess JW, West RB, Neal JW, Wakelee HA.

Lung Cancer. 2015 Jan;87(1):34-8. doi: 10.1016/j.lungcan.2014.11.006. Epub 2014 Nov 15.

PMID:
25443273
25.

Diffuse high intensity PD-L1 staining in thymic epithelial tumors.

Padda SK, Riess JW, Schwartz EJ, Tian L, Kohrt HE, Neal JW, West RB, Wakelee HA.

J Thorac Oncol. 2015 Mar;10(3):500-8. doi: 10.1097/JTO.0000000000000429.

26.

Left behind? Drug discovery in extensive-stage small-cell lung cancer.

Riess JW, Lara PN Jr.

Clin Lung Cancer. 2014 Mar;15(2):93-5. doi: 10.1016/j.cllc.2013.12.010. Epub 2014 Jan 3.

27.

Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era.

Riess JW, Nagpal S, Iv M, Zeineh M, Gubens MA, Ramchandran K, Neal JW, Wakelee HA.

Clin Lung Cancer. 2014 May;15(3):202-6. doi: 10.1016/j.cllc.2013.12.009. Epub 2014 Jan 1.

PMID:
24524822
28.

Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients.

Riess JW, Bhattacharya N, Blenman KR, Neal JW, Hwang G, Pultar P, San-Pedro Salcedo M, Engleman E, Lee PP, Malik R, Wakelee HA.

Immunopharmacol Immunotoxicol. 2014 Apr;36(2):182-6. doi: 10.3109/08923973.2013.864671. Epub 2014 Feb 5.

PMID:
24494587
29.

A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer.

Chen H, Modiano MR, Neal JW, Brahmer JR, Rigas JR, Jotte RM, Leighl NB, Riess JW, Kuo CJ, Liu L, Gao B, Dicioccio AT, Adjei AA, Wakelee HA.

Br J Cancer. 2014 Feb 4;110(3):602-8. doi: 10.1038/bjc.2013.735. Epub 2013 Nov 28.

30.

Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications.

Gandara DR, Li T, Lara PN, Kelly K, Riess JW, Redman MW, Mack PC.

Clin Lung Cancer. 2014 Jan;15(1):1-6. doi: 10.1016/j.cllc.2013.10.001. Epub 2013 Oct 12.

31.

The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era.

Lwin Z, Riess JW, Gandara D.

J Thorac Dis. 2013 Oct;5 Suppl 5:S556-64. doi: 10.3978/j.issn.2072-1439.2013.08.47. Review.

32.

A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors.

Jahchan NS, Dudley JT, Mazur PK, Flores N, Yang D, Palmerton A, Zmoos AF, Vaka D, Tran KQ, Zhou M, Krasinska K, Riess JW, Neal JW, Khatri P, Park KS, Butte AJ, Sage J.

Cancer Discov. 2013 Dec;3(12):1364-77. doi: 10.1158/2159-8290.CD-13-0183. Epub 2013 Sep 26.

33.

Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer.

Ho C, Davies AM, Sangha RS, Lau D, Lara P Jr, Chew HK, Beckett L, Mack PC, Riess JW, Gandara DR.

Invest New Drugs. 2013 Dec;31(6):1587-91. doi: 10.1007/s10637-013-0024-y. Epub 2013 Sep 8.

34.

A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non--small-cell lung cancer patients harboring ROS1 gene rearrangements.

Riess JW, Padda SK, Bangs CD, Das M, Neal JW, Adrouny AR, Cherry A, Wakelee HA.

Clin Lung Cancer. 2013 Sep;14(5):592-5. doi: 10.1016/j.cllc.2013.04.008. Epub 2013 Jun 27. No abstract available.

35.
36.

A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab.

Riess JW, Nagpal S, Das M, Neal JW, Kim JW, Wakelee HA.

J Thorac Oncol. 2013 Feb;8(2):e17-8. doi: 10.1097/JTO.0b013e31827690da. No abstract available.

37.

Targeting fibroblast growth factor receptor and discoidin domain receptor 2 in non-small-cell lung cancer.

Riess JW, Neal JW.

J Thorac Oncol. 2012 Dec;7(16 Suppl 5):S385-6. doi: 10.1097/JTO.0b013e31826df166. Review. No abstract available.

38.

Metastatic non-small cell lung cancer management: novel targets and recent clinical advances.

Riess JW, Wakelee HA.

Clin Adv Hematol Oncol. 2012 Apr;10(4):226-34.

PMID:
22706483
39.

ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy.

Das M, Riess JW, Frankel P, Schwartz E, Bennis R, Hsieh HB, Liu X, Ly JC, Zhou L, Nieva JJ, Wakelee HA, Bruce RH.

Lung Cancer. 2012 Aug;77(2):421-6. doi: 10.1016/j.lungcan.2012.04.005. Epub 2012 May 1.

PMID:
22555222
40.

Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer.

Riess JW, Logan AC, Krupitskaya Y, Padda S, Clément-Duchêne C, Ganjoo K, Colevas AD, Pedro-Salcedo MS, Kuo CJ, Wakelee HA.

Cancer Invest. 2012 Mar;30(3):231-5. doi: 10.3109/07357907.2012.656862.

PMID:
22360362
41.

Targeting FGFR, ephrins, Mer, MET, and PDGFR-α in non-small cell lung cancer.

Riess JW, Neal JW.

J Thorac Oncol. 2011 Nov;6(11 Suppl 4):S1797-8. doi: 10.1097/01.JTO.0000407562.07029.52. No abstract available.

Supplemental Content

Loading ...
Support Center